Detalles de la búsqueda
1.
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials.
Clin Colorectal Cancer;
22(2): 222-230, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36944559
2.
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.
Biomed Pharmacother;
159: 114272, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36706629
3.
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.
Clin Transl Oncol;
24(3): 483-494, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34773566
4.
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
ESMO Open;
6(2): 100062, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33711671
5.
Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM).
ESMO Open;
6(2): 100048, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33556897
6.
MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates with transforming growth factor ß inducing fibrotic responses.
Mucosal Immunol;
14(2): 377-388, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32887938
7.
Controversies in the treatment of RAS wild-type metastatic colorectal cancer.
Clin Transl Oncol;
23(4): 827-839, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32789773
8.
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
Eur J Cancer;
101: 263-272, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30054049
9.
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.
Tumour Biol;
39(6): 1010428317705509, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28621236
10.
SEOM Clinical Guideline of localized rectal cancer (2016).
Clin Transl Oncol;
18(12): 1163-1171, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27905053
11.
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.
Eur J Cancer;
51(11): 1371-80, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25963019
12.
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial.
Ann Oncol;
26(8): 1722-8, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25957330
13.
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.
Br J Cancer;
111(2): 241-8, 2014 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24946000
14.
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Ann Oncol;
23(7): 1919-25, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22156621
15.
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.
Br J Cancer;
102(10): 1468-73, 2010 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-20424611
Resultados
1 -
15
de 15
1
Próxima >
>>